Relations of serum COMP to cardiovascular risk factors and endothelial function in patients with rheumatoid arthritis treated with methotrexate and TNF-α inhibitors. [electronic resource]
Producer: 20121126Description: 1341-7 p. digitalISSN:- 1499-2752
- Adult
- Aged
- Antirheumatic Agents -- therapeutic use
- Arthritis, Rheumatoid -- drug therapy
- Cardiovascular Diseases -- blood
- Cartilage Oligomeric Matrix Protein
- Drug Therapy, Combination
- Endothelium, Vascular -- drug effects
- Extracellular Matrix Proteins -- blood
- Female
- Glucocorticoids -- therapeutic use
- Glycoproteins -- blood
- Humans
- Hyperemia -- blood
- Male
- Matrilin Proteins
- Methotrexate -- therapeutic use
- Middle Aged
- Risk Factors
- Treatment Outcome
- Tumor Necrosis Factor-alpha -- antagonists & inhibitors
No physical items for this record
Publication Type: Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.